KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Bio-Rad Laboratories (BIO) over the last 17 years, with Q4 2025 value amounting to $529.8 million.

  • Bio-Rad Laboratories' Cash & Equivalents rose 854.33% to $529.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $529.8 million, marking a year-over-year increase of 854.33%. This contributed to the annual value of $529.8 million for FY2025, which is 854.33% up from last year.
  • According to the latest figures from Q4 2025, Bio-Rad Laboratories' Cash & Equivalents is $529.8 million, which was up 854.33% from $395.8 million recorded in Q3 2025.
  • In the past 5 years, Bio-Rad Laboratories' Cash & Equivalents registered a high of $859.9 million during Q3 2021, and its lowest value of $369.3 million during Q2 2025.
  • In the last 5 years, Bio-Rad Laboratories' Cash & Equivalents had a median value of $467.5 million in 2021 and averaged $517.9 million.
  • As far as peak fluctuations go, Bio-Rad Laboratories' Cash & Equivalents tumbled by 4215.05% in 2023, and later skyrocketed by 2087.67% in 2024.
  • Bio-Rad Laboratories' Cash & Equivalents (Quarter) stood at $470.8 million in 2021, then dropped by 7.77% to $434.2 million in 2022, then fell by 7.0% to $403.8 million in 2023, then grew by 20.88% to $488.1 million in 2024, then grew by 8.54% to $529.8 million in 2025.
  • Its Cash & Equivalents was $529.8 million in Q4 2025, compared to $395.8 million in Q3 2025 and $369.3 million in Q2 2025.